SCOTT ROCKLAGE- A PIONEER OF VARIOUS NEW DRUG APPLICATIONS

0

Posted by omeditors | Posted in CEO | Posted on 25-05-2017

About Dr. Scott Rocklage

 

His life is an all science-based venture company capital investment. Entrepreneur Dr. Scott Rocklage joined 5 AM Ventures in 2003 as a Venture Partner but later assumed the Managing Partner position the following year.Dr. Rocklage is highly experienced with more than thirty years in healthcare management.

 

This broad experience and strategic responsibility leadership has led him to establish several drugs that even the U.S has approved. These new drug Applications include Teslascan®, Omniscan™, and Cubicin®). Dr. Scott has also partnered with other agencies for multiple clinical drug trials. Dr. Scott has also served as the CEO and Chairman Nycomed Salutar as well as the Cubist Pharmaceuticals. Other organizations that Dr. Rocklage has served include the NASDAQ: RLYP (Relypsa) the former Novira, (now under Johnson Management). He also worked at NASDAQ: EPRS (Epirus), NASDAQ: PULM (Pulmatrix).

 

Dr. Scott is a highly knowledgeable entrepreneur

 

Dr. Scott Rocklage has an incredible education background. He studied at the Berkeley California University he achieved a Chemistry B.S and Ph.D. After the Berkeley California University, he went on to the Massachusetts Institute of Technology where he was involved in Chemistry laboratory research with Richard R. Schrock, the 2005 Chemistry Nobel Prize winner. He is also a medical publisher and has over thirty American reviewed copyrights. Dr. Scott Rocklage is currently based in Boston where his MA offices located.

 

His week is typically tight scheduled. Some days he works with his company’s portfolio management team, studying new life science perspectives while on some days he is in attendance or preparation of Board meetings. Dr. Scott Rocklage gets new ideas by working with other field specialists like business executives, physicians or scientists who help him to shape his ideas into potential outcome medicines that contribute to curing the unmet medical needs.

 

What excites Dr. Scott Rocklage is most excited by the current medical trend where there has been an atomic growth in the capabilities of identifying particular genotypes or mutations to cure some forms of cancer. He considers it a potential way of solving and extending the lives of cancer patients.

 

 

 

Write a comment